Cutera, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
March 05, 2024 at 04:30 pm EST
Share
Cutera, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 46.48 million compared to USD 62.81 million a year ago. Net loss was USD 44.27 million compared to USD 12.13 million a year ago. Basic loss per share from continuing operations was USD 2.22 compared to USD 0.62 a year ago. Diluted loss per share from continuing operations was USD 2.22 compared to USD 0.62 a year ago.
For the nine months, revenue was USD 162.83 million compared to USD 185.05 million a year ago. Net loss was USD 105.6 million compared to USD 74.55 million a year ago. Basic loss per share from continuing operations was USD 5.32 compared to USD 3.95 a year ago. Diluted loss per share from continuing operations was USD 5.32 compared to USD 3.95 a year ago.
Cutera, Inc. develops, manufactures, distributes, and markets energy-based product platforms for medical practitioners, enabling them to offer treatments to their customers. The Company distributes third-party manufactured skincare products and secret systems and consumables. Its system platforms include AviClear, enlighten, excel, truSculpt, Secret PRO, Secret RF, and xeo. The Companyâs Cutera Core segment consists of the Companyâs systems, consumables, skincare, and service businesses. The Cutera Core segment develops, distributes and manufactures energy-based systems for medical practitioners in addition to distributing third-party manufactured skincare products in Japan. The Companyâs AviClear segment consists of the AviClear business. The Companyâs acne solution, AviClear, is a prescription-free, drug-free laser treatment for the treatment of mild to severe acne. Its products include CUTERA, ACUTIP 500, AVITM, AVI360, AVIANALYTICSTM, AVICARE COOLGLIDE, and more.
CUTERA, INC. 
